题名 | The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China |
作者 | |
发表日期 | 2020-07-03
|
DOI | |
发表期刊 | |
EISSN | 1479-5876
|
卷号 | 18期号:1 |
摘要 | BACKGROUND: The novel coronavirus disease 2019 (COVID-19) broke out globally. Early prediction of the clinical progression was essential but still unclear. We aimed to evaluate the timeline of COVID-19 development and analyze risk factors of disease progression. METHODS: In this retrospective study, we included 333 patients with laboratory-confirmed COVID-19 infection hospitalized in the Third People's Hospital of Shenzhen from 10 January to 10 February 2020. Epidemiological feature, clinical records, laboratory and radiology manifestations were collected and analyzed. 323 patients with mild-moderate symptoms on admission were observed to determine whether they exacerbated to severe-critically ill conditions (progressive group) or not (stable group). We used logistic regression to identify the risk factors associated with clinical progression. RESULTS: Of all the 333 patients, 70 (21.0%) patients progressed into severe-critically ill conditions during hospitalization and assigned to the progressive group, 253 (76.0%) patients belonged to the stable group, another 10 patients were severe before admission. we found that the clinical features of aged over 40 (3.80 [1.72, 8.52]), males (2.21 [1.20, 4.07]), with comorbidities (1.78 [1.13, 2.81]) certain exposure history (0.38 [0.20, 0.71]), abnormal radiology manifestations (3.56 [1.13, 11.40]), low level of T lymphocytes (0.99 [0.997, 0.999]), high level of NLR (0.99 [0.97, 1.01]), IL-6 (1.05 [1.03, 1.07]) and CRP (1.67 [1.12, 2.47]) were the risk factors of disease progression by logistic regression. CONCLUSIONS: The potential risk factors of males, older age, with comorbidities, low T lymphocyte level and high level of NLR, CRP, IL-6 can help to predict clinical progression of COVID-19 at an early stage. |
关键词 | |
相关链接 | [Scopus记录] |
收录类别 | |
语种 | 英语
|
学校署名 | 第一
|
资助项目 | Sanming Project of Medicine in Shenzhen[SZSM201612014]
|
WOS研究方向 | Research & Experimental Medicine
|
WOS类目 | Medicine, Research & Experimental
|
WOS记录号 | WOS:000549886900002
|
出版者 | |
Scopus记录号 | 2-s2.0-85087474113
|
来源库 | Scopus
|
引用统计 |
被引频次[WOS]:35
|
成果类型 | 期刊论文 |
条目标识符 | http://sustech.caswiz.com/handle/2SGJ60CL/140694 |
专题 | 南方科技大学医学院 南方科技大学第二附属医院 |
作者单位 | 1.Department of Hepatology,Shenzhen Third People's Hospital,National Clinical Research Center for Infectious Disease,Second Affiliated Hospital,School of Medicine,Southern University of Science and Technology,Shenzhen,29 Bulan Road,518112,China 2.Institute of Reproductive Health,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,China 3.Department of Hepatology,Shenzhen Third People's Hospital,National Clinical Research Center for Infectious Disease,Second Affiliated Hospital,School of Medicine,Southern University of Science and Technology,Shenzhen,29 Bulan Road,518112,China |
第一作者单位 | 南方科技大学医学院; 南方科技大学第二附属医院 |
第一作者的第一单位 | 南方科技大学医学院; 南方科技大学第二附属医院 |
推荐引用方式 GB/T 7714 |
Wang,Fang,Qu,Mengyuan,Zhou,Xuan,et al. The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China[J]. Journal of translational medicine,2020,18(1).
|
APA |
Wang,Fang.,Qu,Mengyuan.,Zhou,Xuan.,Zhao,Kai.,Lai,Changxiang.,...&Liu,Lei.(2020).The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China.Journal of translational medicine,18(1).
|
MLA |
Wang,Fang,et al."The timeline and risk factors of clinical progression of COVID-19 in Shenzhen, China".Journal of translational medicine 18.1(2020).
|
条目包含的文件 | 条目无相关文件。 |
|
除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。
修改评论